The article reviews the importance of glucagon-like peptide-1 (GLP-1) levels in the context of weight regain and insufficient weight loss following metabolic bariatric surgery (MBS). It highlights that while MBS effectively promotes initial weight loss, many patients experience weight regain or insufficient weight loss. Studies show that postprandial GLP-1 levels increase after Roux-en-Y gastric bypass and sleeve gastrectomy, but fasting GLP-1 levels do not significantly change. Higher postprandial GLP-1 levels are associated with successful weight loss, and the use of GLP-1 receptor agonists (GLP-1-RA) has been shown to help patients who have regained weight after MBS. The review also discusses the potential benefits of maintaining higher basal-bolus GLP-1-RA levels as a treatment strategy for individuals who fail to lose weight after MBS. The authors hypothesize that this approach may be promising for managing weight in these patients, potentially by increasing basal GLP-1 levels and blunting metabolic adaptation post-MBS. The article concludes by emphasizing the need for further research to understand the efficacy, safety, and optimal dosing of adjunctive GLP-1-RA therapy in post-MBS patients.The article reviews the importance of glucagon-like peptide-1 (GLP-1) levels in the context of weight regain and insufficient weight loss following metabolic bariatric surgery (MBS). It highlights that while MBS effectively promotes initial weight loss, many patients experience weight regain or insufficient weight loss. Studies show that postprandial GLP-1 levels increase after Roux-en-Y gastric bypass and sleeve gastrectomy, but fasting GLP-1 levels do not significantly change. Higher postprandial GLP-1 levels are associated with successful weight loss, and the use of GLP-1 receptor agonists (GLP-1-RA) has been shown to help patients who have regained weight after MBS. The review also discusses the potential benefits of maintaining higher basal-bolus GLP-1-RA levels as a treatment strategy for individuals who fail to lose weight after MBS. The authors hypothesize that this approach may be promising for managing weight in these patients, potentially by increasing basal GLP-1 levels and blunting metabolic adaptation post-MBS. The article concludes by emphasizing the need for further research to understand the efficacy, safety, and optimal dosing of adjunctive GLP-1-RA therapy in post-MBS patients.